Could Carterra Inc.’s Vega HT-SPR accelerate fragment and small-molecule discovery without compromising rigor
Find out how Carterra Inc.’s Vega HT-SPR platform could redefine primary screening and reshape early drug discovery workflows.
What Biofrontera’s Phase 3 results mean for non-facial actinic keratosis treatment strategies
Biofrontera reports positive Phase 3 Ameluz data outside the face and scalp. Find out how this could change actinic keratosis treatment.
What TG Therapeutics’ ACTRIMS strategy signals about the next competitive phase in anti-CD20 multiple sclerosis therapy
Find out how TG Therapeutics’ ACTRIMS strategy reshapes competition in anti-CD20 multiple sclerosis therapy and what clinicians and regulators are watching next.
Clearmind Medicine Inc. and Polyrizon Ltd. target formulation risk in MEAI’s addiction program
Discover how Clearmind Medicine Inc.’s intranasal MEAI strategy could reshape CNS drug delivery and clinical outcomes. Read the analysis.
Anathapindika Health expands retail footprint, testing detox-first nutraceutical demand in specialty stores
Discover what Anathapindika Health’s AlchePharma retail expansion signals for detox-focused nutraceuticals and the evolving wellness retail landscape.
What Johnson & Johnson’s AKEEGA opinion means for PARP inhibitors beyond castration resistance
Find out how Johnson & Johnson’s CHMP opinion for AKEEGA could shift prostate cancer treatment toward earlier, biomarker-guided precision therapy.
Can Idorsia Pharmaceuticals Ltd’s lucerastat redefine Fabry disease treatment beyond enzyme replacement therapy?
Discover how Idorsia Pharmaceuticals Ltd’s FDA-aligned Phase 3 plan could make lucerastat the first oral therapy for all Fabry disease patients. Read the analysis.
Why Pulmovant’s PHocus study design matters for regulatory confidence in pulmonary hypertension associated with interstitial lung disease
Pulmovant completes PHocus enrollment for mosliciguat in PH-ILD. Find out what this milestone really means ahead of 2026 clinical data.
How Priovant’s brepocitinib advances a long-overlooked inflammatory skin disease toward approval
Strong Phase 2 data put brepocitinib on a rare pivotal path in cutaneous sarcoidosis. Find out what this changes for clinicians and regulators.
Can Ampligen plus durvalumab finally overcome immunotherapy resistance in metastatic pancreatic cancer
Explore what AIM ImmunoTech’s Ampligen Phase 2 data could change for pancreatic cancer immunotherapy and what risks still remain.